Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

Clinical Cancer Research

Volumn 16, Issue 1, 2010, Pages 203-211

  Armstrong, Andrew J ^a   Garrett Mayer, Elizabeth ^b   De Wit, Ronald ^c   Tannock, Ian ^d   Eisenberger, Mario ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF TORONTO   (Canada)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; DOCETAXEL; HEMOGLOBIN; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL PROTOCOL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNAL VALIDITY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NOMOGRAM; PERFORMANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN BLOOD LEVEL; TREATMENT DURATION;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASM METASTASIS; NOMOGRAMS; PAIN MEASUREMENT; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 74949112755     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2514     Document Type: Article

References (25)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Tannock IF, de WR, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
3. Attard G, Yap TA, Reid AH, et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J Clin Oncol (Meeting Abstracts) 2007;25:5063.
4. Attard G, Reid AH, A'hern R, et al. Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. J Clin Oncol 2009;27:3742-8.
5. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009;324:787-90.
6. Armstrong AJ, Garrett-Mayer ES, Yang YC, de WR, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13:6396-403.
7. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21:1232-7.
8. Smaletz O, Scher HI, Small EJ, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972-82.
9. Garmey EG, Sartor O, Halabi S, Vogelzang NJ. Second-line chemotherapy for advanced hormone-refractory prostate cancer. Clin Adv Hematol Oncol 2008;6:118-32.
10. Rosenberg JE, Small EJ. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer 2004;3:122-4.
11. WHO Criteria. WHO handbook for reporting results of cancer treatment. 48 ed. Geneva: World Health Organization; 1979.
12. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277-99.
13. Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
14. Berthold DR, Pond GR, de WR, Eisenberger M, Tannock IF. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53.
15. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009;27:2766-71.
16. Hussain M, Goldman B, Tangen C, et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol 2009;27:2450-6.
17. Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27:2874-80.
18. Schellhammer PF, Higano C, Berger ER, et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). AUA Annual Meeting. Chicago; 2009.
19. Chi KN, Hotte SJ, Yu E, et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (Meeting Abstracts) 2009;27:5012.
20. Beer TM, Ryan CW, Venner PM, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). J Clin Oncol (Meeting Abstracts) 2005;23:4516.
21. Petrylak D, Sartor O, Witje F, et al. A Phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Prostate Cancer Sympsium [abstract 145] 2007.
22. Berthold DR, Pond G, De Wit R, Eisenberger MA, Tannock IF. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol (Meeting Abstracts) 2006;24:4516.
23. Sella A, Sternberg CN, Skoneczna I, Kovel S. Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer. BJU Int 2008;102:1607-9.
24. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res 2007;13:1488-92.
25. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.